Roxadustat for Anemia in Patients With CKD

Last updated: January 19, 2021
Sponsor: Shenzhen Second People's Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Chronic Renal Anemia

Anemia

Treatment

N/A

Clinical Study ID

NCT04502537
20203357012
  • Ages > 18
  • All Genders

Study Summary

A number of RCT studies have shown the safety and effectiveness of oral Roxadustat in the treatment of renal anemia, but there is a lack of evidence from cohort studies. A prospective cohort study is planed to conduct to evaluate the efficacy and safety of Roxadustat for renal anemia in the real world.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. the patient did not receive ESA treatment.The average Hb level of the last two (atleast 7 days before the start of the study treatment and during the screening period)was <10 g/dL. Or patients who have received ESA: Patients with renal anemia who received ESA for at least 4 weeks within the approveddose range in China before the screening evaluation.
  2. The average Hb level of the last two (at least 7 days before the start of the studytreatment and during the screening period) >=7 g/dL and <=12.0 g/dL;
  3. The expected survival time is more than 1 year;

Exclusion

Exclusion Criteria:

  1. a history of severe, chronic, end-stage or uncontrolled autoimmune liver disease,Child Pugh score was grade C, or with active hepatitis;
  2. preparing for pregnancy or pregnancy or lactation;
  3. having anemia caused by any other disease other than CKD, such as thalassemia, sicklecell anemia, pure red aplastic anemia, hemolytic anemia, tumor-related anemia,chemotherapy-related anemia, and myelodysplastic syndrome;
  4. malignant tumor, such as prostate cancer, breast cancer, renal cell cancer or anyother malignant tumor history or diagnosed
  5. .Any red blood cell infusion during the screening period;
  6. The patient is known to be allergic to the active substance (Roxadustat) or anyexcipient of the product;

Study Design

Total Participants: 200
Study Start date:
February 01, 2021
Estimated Completion Date:
September 30, 2023

Study Description

The prevalence of anemia in patients with chronic kidney disease (CKD) (15.4%) is twice that of the general population (7.6%), and the degree of anemia increases with the severity of CKD. A number of RCT studies have shown the safety and effectiveness of oral Roxadustat in the treatment of renal anemia, but there is a lack of evidence from cohort studies. A prospective cohort study is planed to conduct to evaluate the efficacy and safety of Roxadustat for renal anemia in the real world. It is planned to continuously recruit patients with renal anemia in Shenzhen Second People's Hospital from October 2020 to June 2023. The treatment of anemia will be recorded (Roxadustat or erythropoietin), and the observation period is one year. Collect the patient's demographic characteristics, drug dosage, adjustment plan, hemoglobin. The main outcome indicators were: the average change in Hb from baseline to 28-52 weeks, and the Hb response rate reached during two consecutive visits; the secondary outcome indicators were: the maintenance rate of the target Hb level, iron metabolism indicators, 0 to 8 weeks of Hb level increase rate, dose adjustment and safety indicators. The generalized additive mixed model of repeated measures was used to analyze the changes and differences of outcome indicators in different groups. Expected results: In the cohort study, the effectiveness and safety of roxastat in the treatment of renal anemia, the starting dose and the adjustment plan, provide a basis for guiding the clinical safe and effective application of roxastat.

Connect with a study center

  • Shenzhen Second People's Hospital

    Shenzhen,
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.